John Fallon - EXACT Sciences Director

EXAS Stock  USD 63.24  0.29  0.46%   

Director

Dr. John A. Fallon, M.D. is Independent Director of the Company. Dr. Fallon has served as a director since January 2016. Dr. Fallon served as Senior Vice President and Chief Physician Executive at Blue Cross Blue Shield of Massachusetts from 2004 through 2015. Prior to his role at BCBS MA, Dr. Fallon served as Chief Executive Officer for clinical affairs at the State University of New York Downstate Medical Center, including University Hospital of Brooklyn and the clinical faculty practice plan. His professional experience also includes the Partners Healthcare System, where he was chairman of the physician network. Dr. Fallon was also the founder and CEO of North Shore Health System, a large physicianhospital organization in Massachusetts. He serves on the boards of directors of Insulet Corporationrationration, a medical devices company, AMAG Pharmaceuticals, Inc., a specialty pharmaceutical company and Collegium Pharmaceuticals, Inc., a specialty pharmaceutical company, as well as the board of Network for Excellence in Health Innovation, a notforprofit institution. Dr. Fallon also previously served on the National Committee for Quality Assurance Medical Standards Committee and the New England Comparative Effectiveness Public Advisory Council . Dr. Fallon practiced internal medicine for more than 20 years, fulfilled his residency at Boston City Hospital, is Board Certified in Internal Medicine and is a fellow of the American College of Physicians since 2016.
Age 70
Tenure 8 years
Professional MarksMBA
Address 5505 Endeavor Lane, Madison, WI, United States, 53719
Phone608 284 5700
Webhttps://www.exactsciences.com
Fallon earned a bachelor degree from the College of the Holy Cross, an MBA from the University of South Florida and a Doctor of Medicine from Tufts University School of Medicine.

EXACT Sciences Management Efficiency

The company has return on total asset (ROA) of (0.0304) % which means that it has lost $0.0304 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.066) %, meaning that it created substantial loss on money invested by shareholders. EXACT Sciences' management efficiency ratios could be used to measure how well EXACT Sciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.1 in 2024. Return On Capital Employed is likely to drop to -0.04 in 2024. At this time, EXACT Sciences' Debt To Assets are comparatively stable compared to the past year. Asset Turnover is likely to gain to 0.41 in 2024, whereas Return On Tangible Assets are likely to drop (0.1) in 2024.
The company currently holds 2.55 B in liabilities with Debt to Equity (D/E) ratio of 0.77, which is about average as compared to similar companies. EXACT Sciences has a current ratio of 2.43, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist EXACT Sciences until it has trouble settling it off, either with new capital or with free cash flow. So, EXACT Sciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like EXACT Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for EXACT to invest in growth at high rates of return. When we think about EXACT Sciences' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

William BoehmNeogen
70
Robert MittelstaedtLaboratory of
74
Elisha FinneyMettler Toledo International
59
Darci VetterNeogen
43
Gary GillilandLaboratory of
63
Kerrii AndersonLaboratory of
63
Richard CrowderNeogen
56
Bryan BrokmeierWaters
N/A
Sam SamadIDEXX Laboratories
48
Robert WilliamsLaboratory of
72
Michael KellyMettler Toledo International
64
Frederick CravesTwist Bioscience Corp
72
Jack ParnellNeogen
82
Richard FrancisMettler Toledo International
52
Connie HarveyMettler Toledo International
52
Xiaoying MaiTwist Bioscience Corp
30
Sophie VandebroekIDEXX Laboratories
56
Daniel JuniusIDEXX Laboratories
65
Jeffrey DavisLaboratory of
57
Francis ContinoMettler Toledo International
70
James TobinNeogen
61
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin. Exact Sciences operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 6420 people. EXACT Sciences (EXAS) is traded on NASDAQ Exchange in USA. It is located in 5505 Endeavor Lane, Madison, WI, United States, 53719 and employs 6,500 people. EXACT Sciences is listed under Biotechnology category by Fama And French industry classification.

Management Performance

EXACT Sciences Leadership Team

Elected by the shareholders, the EXACT Sciences' board of directors comprises two types of representatives: EXACT Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of EXACT. The board's role is to monitor EXACT Sciences' management team and ensure that shareholders' interests are well served. EXACT Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, EXACT Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Katherine Napier, Independent Director
Sally Crawford, Independent Director
Jeffrey Elliott, CFO
Kevin Conroy, Chairman of The Board, CEO and Pres
James Doyle, Independent Director
Ana Hooker, Senior Vice President Operations
Thomas Carey, Independent Director
John Fallon, Director
Scott Johnson, Senior Vice President Research & Development
Daniel Levangie, Independent Director
Vic Parker, Head Sales
John Bakewell, CFO
Sri Kalluri, Chief Officer
Nassar Nizami, Chief Officer
William Megan, Principal Financial Officer and Sr. VP of Fin.
Scott Coward, Sr. VP and General Counsel
Pierre Jacquet, Director
Graham Lidgard, Chief Science Officer and Sr. VP
Jorge Garces, Chief Officer
Jeffrey CFA, Chief Officer
David Thompson, Lead Independent Director
Michael Wyzga, Director
Lionel Sterling, Independent Director
James Herriott, General VP
Andrew Slavitt, Director
Sarah Condella, Executive Resources
Mark Stenhouse, President Cologuard
Tim Caprez, Chief VP
Kathleen Sebelius, Director
Everett Cunningham, Chief Officer
Maneesh Arora, COO, Sr. VP and Director
Katherine Zanotti, Independent Director
Eli Casdin, Independent Director
Megan Jones, Associate Relations

EXACT Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is EXACT Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

EXACT Sciences Investors Sentiment

The influence of EXACT Sciences' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in EXACT. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to EXACT Sciences' public news can be used to forecast risks associated with an investment in EXACT. The trend in average sentiment can be used to explain how an investor holding EXACT can time the market purely based on public headlines and social activities around EXACT Sciences. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
EXACT Sciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for EXACT Sciences' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average EXACT Sciences' news discussions. The higher the estimated score, the more favorable is the investor's outlook on EXACT Sciences.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards EXACT Sciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, EXACT Sciences' short interest history, or implied volatility extrapolated from EXACT Sciences options trading.

Pair Trading with EXACT Sciences

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if EXACT Sciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in EXACT Sciences will appreciate offsetting losses from the drop in the long position's value.

Moving together with EXACT Stock

  0.71ACB Aurora Cannabis TrendingPairCorr

Moving against EXACT Stock

  0.42JNJ Johnson Johnson Aggressive PushPairCorr
The ability to find closely correlated positions to EXACT Sciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace EXACT Sciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back EXACT Sciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling EXACT Sciences to buy it.
The correlation of EXACT Sciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as EXACT Sciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if EXACT Sciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for EXACT Sciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether EXACT Sciences is a strong investment it is important to analyze EXACT Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact EXACT Sciences' future performance. For an informed investment choice regarding EXACT Stock, refer to the following important reports:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in EXACT Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
For more information on how to buy EXACT Stock please use our How to Invest in EXACT Sciences guide.
Note that the EXACT Sciences information on this page should be used as a complementary analysis to other EXACT Sciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for EXACT Stock analysis

When running EXACT Sciences' price analysis, check to measure EXACT Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EXACT Sciences is operating at the current time. Most of EXACT Sciences' value examination focuses on studying past and present price action to predict the probability of EXACT Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EXACT Sciences' price. Additionally, you may evaluate how the addition of EXACT Sciences to your portfolios can decrease your overall portfolio volatility.
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Equity Valuation
Check real value of public entities based on technical and fundamental data
Is EXACT Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of EXACT Sciences. If investors know EXACT will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about EXACT Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.13)
Revenue Per Share
13.876
Quarterly Revenue Growth
0.17
Return On Assets
(0.03)
Return On Equity
(0.07)
The market value of EXACT Sciences is measured differently than its book value, which is the value of EXACT that is recorded on the company's balance sheet. Investors also form their own opinion of EXACT Sciences' value that differs from its market value or its book value, called intrinsic value, which is EXACT Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because EXACT Sciences' market value can be influenced by many factors that don't directly affect EXACT Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between EXACT Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if EXACT Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, EXACT Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.